ORGO — Organogenesis Holdings Inc.

Summary of Organogenesis Holdings, Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Net Revenue: $36.3 million, a 58% decline year-over-year.
• Advanced Wound Care Revenue: $29.5 million, down 63%.
• Surgical & Sports Medicine Revenue: $6.8 million, flat year-over-year.
• Gross Profit: $10.5 million (29% of net revenue), down from 73% last year; non-GAAP gross profit at $14.8 million (41%).
• Operating Expenses: $106.1 million, a decrease of 6% year-over-year.
• Operating Loss: $68.9 million, compared to a loss of $26.7 million last year.
• Net Loss: $53.2 million, up from $18.8 million year-over-year; adjusted net loss of $43.7 million.
• Cash Position: $92.1 million as of March 31, 2026, with no debt.

2. Strategic Updates and Business Highlights

• The company completed a BLA submission for its ReNu program, targeting knee osteoarthritis, marking a significant milestone.
• A randomized controlled trial for PuraPly AM demonstrated significant efficacy in treating non-healing diabetic foot ulcers, supporting its future inclusion in coverage policies.
• Despite revenue declines, the company believes it has gained market share, particularly in the Advanced Wound Care segment.

3. Forward Guidance and Outlook

• 2026 Total Revenue Guidance: Revised to $270 million to $310 million, reflecting a decline of 45% to 52% year-over-year, a more pessimistic outlook compared to previous estimates.
• Anticipated sequential revenue growth in the second half of 2026, with a return to normalized profitability expected in Q4.
• Operating expenses are projected to decrease by approximately 25% year-over-year, with significant cost savings from a recent restructuring.

4. Bad News, Challenges, or Points of Concern

• The company faces significant market disruption due to changes in reimbursement policies and clinician confusion stemming from CMS comments on skin substitutes.
• The Advanced Wound Care market has contracted by approximately 63%, impacting revenue expectations.
• Uncertainty regarding the timing of CMS clarifications on wastage policies adds to the operational challenges.
• The operating loss has substantially increased, indicating financial strain during the transition period.

5. Notable Q&A Insights

• Management acknowledged that the complexity of reimbursement changes was greater than anticipated, leading to unexpected disruptions.
• There is no clear timeline for when CMS will provide clarity on wastage policies, but the company is actively engaging with them.
• Confidence in a recovery in the second half of the year is based on month-over-month improvements observed in early 2026 and expectations of reduced customer confusion and altered competitive dynamics.

Overall, while Organogenesis Holdings is navigating significant challenges in the current market environment, it remains optimistic about future growth and market share gains, supported by ongoing regulatory and clinical advancements.